Xinhua Pharmaceutical Wins NMPA Approval for New Electrolyte Injection

The latest update is out from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ).

Shandong Xinhua Pharmaceutical Company Limited has obtained a Drug Registration Certificate from China’s National Medical Products Administration for its Sodium Potassium Magnesium and Calcium Concentrated Solution for Injection. The approval covers a 20ml prescription injectable classified as a Class 3 chemical drug for domestic production, with finalized standards on quality, labeling, instructions and production processes required before commercial rollout.

The new authorization strengthens Xinhua Pharmaceutical’s injectable product portfolio and supports its positioning as a regulated supplier to China’s clinical and hospital market. By securing regulatory clearance, the company can move toward compliant manufacturing and eventual sales of the product, which may enhance its competitiveness and broaden treatment options for healthcare providers once production and quality management requirements are fully met.

The most recent analyst rating on (HK:0719) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Shandong Xinhua Pharmaceutical Company Limited Class H stock, see the HK:0719 Stock Forecast page.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Company Limited is a PRC-based drug manufacturer listed in Hong Kong and Shenzhen, operating in the pharmaceutical industry with a focus on prescription medicines. The company develops and produces chemical preparations and active pharmaceutical ingredients, serving hospital and clinical markets in China and potentially overseas through regulated drug registrations.

Average Trading Volume: 1,024,764

Technical Sentiment Signal: Buy

Current Market Cap: HK$9.64B

For a thorough assessment of 0719 stock, go to TipRanks’ Stock Analysis page.